Exelixis Inc (EXEL)

0 followers ·
Sector:HEALTH CARE
Industry:BIOTECHNOLOGY & LIFE SCIENCES
SIC:BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:Michael M. Morrissey
Employees:1,220
Web site:exelixis.com
1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502
6508377000
All 13F FilersPriorChangeHedge Funds 1PriorChange
Exelixis, Inc. focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. Its products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma.
Please log in first to see chart
-1
Investor
History
Shares Held or Principal Amt
Market Value
% of Portfolio
Previous % of Portfolio
Rank
Change in Shares
% Change in Shares
% Ownership
Qtr 1st Owned
Est. Avg Price
Source
Source Date
Date Reported
No data available